FDA Brief

Warning letters Drugs

FDA warning letter to

Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy

High riskIssued Feb 1, 2021Posted Feb 9, 2021Division of Pharmaceutical Quality Operations IV

Kona Community Hospital Pharmacy prepared sterile drugs in insanitary conditions with microbial contamination and facility flaws.

What happened

FDA inspected the pharmacy from December 2 to December 13, 2019, and issued a Form FDA 483 (inspection observations form) on December 13, 2019. FDA found sterile drug products were prepared under insanitary conditions, including repeated microbial contamination in cleanrooms and sterile work hoods/cabinets, deficient facility design, inadequate smoke studies, and use of a non-sterile disinfectant in the sterile processing area. FDA said the pharmacy’s January 3, 2020 response did not include enough information or documentation to fully evaluate some corrective actions.

What FDA found

  1. Sterile drug products were prepared under insanitary conditions that could contaminate them, making them adulterated under the law.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. The pharmacy did not fix repeated microbial contamination found in cleanrooms and sterile work hoods/cabinets and did not evaluate its impact on drugs.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  3. The cleanroom design was deficient, including an unclamped HEPA filter that had failed leak testing and was not leak-tested in 2019, air returns near supply vents, and doors that could be open at the same time.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  4. The pharmacy could not maintain a differential pressure cascade between rooms of higher and lower air quality when cleanroom doors were closed, and air supply vents had apparent dust.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  5. The pharmacy did not perform adequate smoke studies under dynamic conditions to show unidirectional airflow in the ISO 5 biological safety cabinet.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  6. The pharmacy used a non-sterile disinfectant in the ISO 5 aseptic processing area.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]

What FDA wants

Within 15 working days, notify FDA in writing of specific corrective steps, prevention steps, and documentation; if corrections cannot be completed, state why and give a completion date. FDA also strongly recommends a comprehensive assessment of operations, including aseptic processing, with a third-party consultant who has sterile drug manufacturing expertise.

Who should pay attention

  • patients receiving compounded sterile drugs from hospital pharmacies
  • hospitals and health systems that use compounded sterile products
  • compounding pharmacies with sterile cleanrooms

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk